












Here	 we	 present	 2shRNA,	 a	 shRNA-based	 nanobinder	 that	 can	
simultaneously	 attack	 two	 therapeutic	 targets	 involved	 in	 drug	
resistance	 pathways,	 and	 that	 can	 additionally	 bind	 accessory	
molecules	 such	 as	 cell	 targeting	 peptides	 or	 fluorophores.	 We	
create	 2shRNAs	 designed	 to	 specifically	 kill	 HER2+	 breast	 cancer	
cells	in	the	absence	of	transfecting	agent.	
Acquired	 resistance	 to	 molecularly	 targeted	 therapies	 is	 a	 major	
limitation	for	the	successful	treatment	of	cancer,1	as	in	many	cases,	
rescue	 pathways	 are	 activated	 in	 response	 to	 perturbation	 of	 the	
major	 pathway,2	 leading	 to	 patient	 relapse.	 Approaches	 to	 fight	
resistance	consist	 in	changes	of	treatment	or	 in	the	administration	
of	 combination	 of	 drugs	 used	 to	 attack	 primary	 and	 rescue	
pathways.3	 Unfortunately,	 most	 drug	 combinations	 approved	 to	
date	 face	major	hurdles,3b	 such	as	 toxicity	 effects,	which	hampers	
their	clinical	use	forcing	the	development	of	new	efficient	and	non-
toxic	 combinatorial	 approaches.	An	alternative	 strategy	consists	 in	
the	simultaneous	inactivation	of	both	primary	and	rescue	pathways	
by	using	RNA	interference	(RNAi)	machinery	(siRNAs	and	shRNAs).4 
Following	 this	 approach	undruggable	proteins	 can	be	 tackled	with	
large	 specificity.4cd	 Unfortunately,	 shortcomings	 exist,	 the	 most	
important	 ones	 related	 to	 poor	 bio-disponibility4cd	 and	 to	 the	
difficulty	 of	 controlling	 the	 concentration	 of	 the	 two	 RNAs	 inside	
the	cell.4cd	
	 In	 the	 search	 of	 innovative	 and	 efficient	 RNAi	 chemistries,	we	
recently	 developed	 a	 N-hexyl-N	 dimeric	 nucleoside	 unit	 (BC6;	 Fig.	
1A)	 with	 very	 interesting	 structural	 properties,	 such	 as	 high	





the	 second	 leading	 cause	 of	 death	 in	 women	 in	 developed	
countries.7	 In	 recent	 years	 targeted	 therapies	 against	 BC	 have	
gained	 importance,2	 especially	 those	 targeting	 HER2,8	 a	
transmembrane	 tyrosine	 kinase	 belonging	 to	 a	 surface	 receptor	
family	 that	 includes	epidermal	growth	factor	receptor.9	The	use	of	
monoclonal	antibody	 trastuzumab	 (Herceptin®),10	and	the	 tyrosine	
kinase	inhibitor	Lapatinib	(Tykerb®),11	which	interfere	HER2	activity,	
results	 in	stopping	proliferation,	 leading	to	major	 improvements	 in	
patient	 survival.10,11	Unfortunately,	 long	 term	 treatment12	 leads	 to	
the	overexpression	of	oncogenes	involved	in	BC	metastatic	spread,	
such	as	GRB7,13	STARD313c,14	and	Hsp27,15	leading	to	resistance.	It	is	
tempting	 to	 believe	 that	 combination	 of	 siRNAs	 in	 a	 branched	




of	 different	 sequence	 in	 a	 branched	 structure,	 which	 might	
have	 great	 potential	 to	 inhibit	 two	 different	 genes	
simultaneously.	To	this	end,	we	devised	a	bifunctional	shRNA-
based	 branched	 nanobinder	 (2shRNA;	 Fig.	 1B)	 composed	 of	
three	 building	 blocks:	 two	 BC6-loop	 RNA	 hairpins	 (arms;	 An	
and	Bn)	 with	 3'-overhangs	 (sticky	 ends)	 that	 form	 base-pairs	
with	 the	 3'-sticky	 ends	 of	 a	 central	 two-way	 junction	 (Cn)	
formed	by	a	natural	RNA	strand	 (CBn)	and	 its	complementary	
counterpart	(CTn), which	possesses	an	internal	BC6	bulge.	The	
building	 blocks	 are	 designed	 to	 spontaneously	 self-assemble	
into	a	branched	structure	after	hybridization.	
					Molecular	 Dynamics	 (MD)	 simulations	 revealed	 that	 the	
presence	 of	 the	 BC6-loops	 and	 the	 BC6	 internal	 bulge	 introduce	
little	changes	in	the	structure	of	the	two	double-stranded	arms	(Fig.	
S10,	ESI†),	but	produces	a	 local	bending	at	 the	bulge	generating	a	
two-way	 branched	 architecture	 with	 very	 well-defined	 arms	 (Fig.	
1C),	 which	 should	 make	 them	 accessible	 to	 RNAi	 machinery.	
Encouraged	 by	 these	 simulations	 we	 synthesized	 two	 branched	
RNAs	 specifically	 designed	 to	 attack	 two	 combinations	 of	 targets	
involved	 in	 drug	 resistance	 pathways	 in	 HER2+	 BC:	 2shSG	 and	






(CT1:CB1)	 and	 in	 the	 3'-sticky	 ends	 (Fig.	 S5,	 ESI†),	 differing	 only	 in	
the	 base-paired	 sequence	 of	 their	 hairpin	 components	 [A1	
(targeting	 STARD3)	 and	 B1	 (targeting	 GRB7)	 in	 2shSG,	 and	 A2	
(targeting	Hsp27)	and	B1	in	2shHG].	This	design	allows	us	to	test	an	
unlimited	 number	 of	 target	 combinations	 in	 a	 straightforward	
manner	 by	 changing	 only	 the	 hairpin	 components	 each	 time	 we	
need	to	target	a	different	combination	of	genes.	To	further	validate	
this	 design,	 we	 prepared	 2shRG,	 targeting	 the	 Renilla	 luciferase	
(A3)/GRB7(B1)	 combination	 (Fig.	 1D).	 Finally,	 as	 a	 non-targeting	
negative	 control,	 we	 constructed	 2shRR,	 with	 both	 arms	 (A4	 and	
B2)	 targeting	 Renilla	 mRNA	 and	 with	 central	 joint	 (CT2:CB2)	 and	
sticky	ends	different	to	those	of	the	other	three	systems	(Fig.	1D).	
				Formation	 of	 the	 branched	 nanostructures	 proceeded	 in	 a	 very	
straightforward	 and	 specific	 manner	 (Fig.	 S1A	 and	 S2,	 ESI†)	 by	
combination	 of	 the	 four	 building	 blocks	 of	 each	 of	 the	 branched	
RNAs	 (which	 possess	 specifically	 designed	 complementary	 sticky	
ends)	 under	 annealing	 conditions.	 As	 an	 example,	 analysis	 of	 the	
formation	of	2shSG	by	native	PAGE	revealed	a	single	product	(~80	
bp;	 Fig.	 S1A)	 that	 migrated	 more	 slowly	 than	 each	 of	 the	 four	
separated	 RNA	 building	 blocks	 and	 similarly	 to	 its	 “covalent”	
branched	RNA	analogue	 (with	each	of	 the	 four	components	 linked	
between	them	by	phosphodiester	bonds;	Fig.	S3,	ESI†;).	
				2shSG	 turned	out	 to	be	a	good	 substrate	of	Dicer,	which	 slowly	
converted	 it	 into	 sequences	 ~19	 bp	 (Fig.	 S1B).	 The	 central	 part	






in	 the	 presence	 of	 Lipofectamine	 2000.	 2shSG	 caused	 strong	
inhibition	 of	 expression	 of	 STARD3	 and	 GRB7	 (85%	 and	 95%	
knockdown;	Fig.	2A;	Fig.	S6,	ESI†),	with	activities	similar	to	those	of	






























				RNAi-mediated	 silencing	 of	 GRB7,	 STARD3	 and	 Hsp27	
(independently)	is	known	to	decrease	the	viability	of	HER2+	BC	
cells	 such	 as	 SK-BR-3	 and	 BT-474	 [Lapatinib	 (Lap)-
sensitive).13ac,15	Moreover,	 it	has	been	found	that	suppression	
of	 GRB7	 by	 siRNAs	 increases	 the	 activity	 of	 Lap	 in	 these	 cell	
lines13a	and	that	Hsp-27	removal	increases	the	susceptibility	of	
HER2+	 drug-resistant	 BC	 cells	 to	 HER2	 inhibitors.15	 To	
investigate	 the	 potential	 beneficial	 effect	 of	 the	 branched-
mediated	knockdown	of	GRB7/STARD3	and	GRB7/	Hsp27	gene	
combinations	 on	 BC	 therapy,	 we	 carried	 out	 a	 cell	 viability	




2shSG	 and	 2shHG	 was	 significantly	 reduced	 (Fig.	 2D),	 compared	
with	 cells	 transfected	 with	 mixtures	 of	 natural	 targeting	 RNAs	 [II	
(GRB7)	+	III	(STARD3)	and	II	+	IV	(Hsp27)],	with	(52	±	2)%	and	(46	±	
2)%	decrease	in	cell	proliferation	for	2shSG	and	2shHG	versus	(32	±	
2)%	 and	 (25	 ±	 5)%	 for	 mixtures	 of	 siRNAs	 II	 +	 III	 and	 II	 +	 IV.	 As	
expected,	 cells	 were	 unaffected	 when	 treated	 with	 non-targeting	
branched	RNA	(2shRR)	 (Fig.	2D).	The	combination	of	Lap	with	the	
targeting	2shRNAs	leads	to	a	dramatic	decrease	on	cell	proliferation	




				Similar	 results	were	obtained	with	 the	BT-474	cell	 line	 (Fig.	
2E),	 thus	confirming	the	higher	anti-proliferative	effect	of	 the	
branched	 systems,	 both	 alone,	 or	 in	 combination	 with	 Lap.	
Very	 interestingly,	 treatment	 of	 the	 Lap-resistant	 HER2+	 BC	
cell	 line	 UACC-73217	 with	 2shSG	 and	 2shHG	 caused	 a	
significant	 decrease	 in	 cell	 proliferation,	 compared	 with	
untreated	cells	and	cells	treated	with	non-targeting	2shRR	(Fig.	
2F)	 or	 with	 the	 central	 part	 CB1:CB1	 (Fig.	 S8,	 ESI†).	 Very	
encouragingly,	 the	 decrease	 in	 proliferation	 caused	 by	2shSG	






higher	 than	 that	 of	 the	 corresponding	mixtures	 of	 siRNAs	 (II	 +	 III	
and	 II	 +	 IV)	 and	 significantly	 lower	 than	 the	 corresponding	
2shRNAs	 containing	 them	 (2shSG	 and	 2shHG;	 Fig.	 S8,	 ESI†),	
confirming	 the	 efficiency	 of	 the	 BC6-loop	 shRNA	 design	 and	
the	 synergistic	 effect	 achieved	with	 our	 branched	 co-delivery	







Fig.	 2	 (A-C)	Western	 blot	 analysis	 and	 plot	 of	 inhibition	 of	Renilla	




(P	 <	0.01),	***	 (P	 <	0.001)	and	****	 (P	 <	0.0001)	 versus	 indicated	
samples;	 #	 (P	 <	 0.05),	 ##	 (P	 <	 0.01)	 and	 ####	 (P	 <	 0.0001)	 versus	
vehicle	in	the	absence	of	Lap. 
	RNAs	(Fig.	2G),	confirming	the	low	toxicity	of	our	RNA	design.	
				To	 further	 increase	 the	 therapeutic	 potential	 of	 the	
branched	 construct,	 we	 proceeded	 to	 functionalize	 it	 with	
accessory	 molecules.	 With	 this	 aim,	 we	 converted	 one	







cancer	 cells,19	 and	A2'	 and	B1'	 were	 reacted	with	 the	 azido-
derivative	 of	 two	 different	 fluorophores:	 Cy5	 and	 carboxy-
fluorescein	 (FAM)	 (red	 and	 green	 fluorescent	 signals,	
respectively),	to	give	A2-Cy	and	B1-FAM	(Fig.	3,	Fig.	S4,	ESI†).	
				We	used	 these	 conjugates	 to	 construct	a	 variety	of	mono-,	
di-	 and	 tri-functionalized	 2shHG	 derivatives,	 by	 hybridization	
of	 the	appropriate	building	blocks	 (Fig.	3	and	Fig	S5,	ESI†):	 (i)	
2shHG-AHNP,	 (ii)	 2shHG-AHNP-FAM,	 (iii)	 2shHG-AHNP-Cy5,	
(iV)	2shHG-AHNP-FAM-Cy,	and	(v)	2shHG-FAM-Cy.		
				To	confirm	the	co-delivery	efficiency	of	our	 technology,	SK-
BR-3	 cells	 were	 incubated	 with	 dual-labelled	 2shHG-FAM-Cy	
(Fig.	 4A-D;	 40	 nM)	 in	 the	 presence	 of	 Lipofectamine.	 As	 a	
control,	 we	 used	 a	 mixture	 of	 equimolar	 amounts	 of	
fluorescently	 labelled	 siRNA	 analogues	 siRNA	 IV-Cy	 (red)	 and	
siRNA	 II-FAM	(green)	(Fig.	4E-H;	Fig.	S5,	ESI†;	40	nM	each).	 In	
the	 case	 of	 cells	 treated	 with	 2shHG-FAM-Cy,	 both	 dyes	 co-
localized	 in	 a	 single	 point	 (Fig.	 4D),	 thus	 confirming	 that	 the	
branched	 RNA	 enters	 the	 cell	 and	 delivers	 the	 two	 shRNAs	
simultaneously.	 In	 contrast,	 in	 the	 case	 of	 cells	 treated	 with	
the	 mixture	 of	 siRNAs	 (Fig.	 4E-H)	 an	 uneven	 and	 random	
distribution	 of	 both	 dyes	 is	 observed,	 due	 to	 different	
transfection	 efficiencies.	 Moreover,	 fluorescence	 intensities	
are	lower	than	in	the	case	of	cells	treated	with	2shHG-FAM-Cy	
[Fig.	 4E	 versus	 Fig.	 4A	 (recorded	 using	 the	 same	 instrument	
settings)	 and	 Fig.	 4F	 versus	 Fig.	 4B	 (recorded	 using	 the	 same	
instrument	 settings)].	 These	 results	 confirm	 the	 robustness,	
efficiency	 and	 potential	 advantages	 of	 our	 technology,	
compared	with	classical	siRNA	approaches.	
				We	next	 explored	 the	ability	of	 Tat-AHNP-bearing	2shRNAs	
to	enter	HER2+	BC	 cells	 in	 the	absence	of	 transfecting	agent.	
As	 indicated	by	 the	green	 fluorescence	signal	detected	 in	Fig.	
S9C,	 2shHG-AHNP-FAM	 (100	 nM)	 efficiently	 internalized	 into	
HER2+	SK-BR-3	cells.	Similar	results	were	obtained	with	its	Cy5	
analogue	 2shHG-AHNP-Cy	 (Fig.	 S9D).	 In	 contrast,	 no	
appreciable	 entry	was	 observed	when	 the	 same	 cell	 line	was	
treated	 with	 2shHG-FAM-Cy,	 lacking	 the	 AHNP	 carrier	 (Fig.	
S9F,G).	 Tat-AHNP-mediated	 specificity	 was	 further	 confirmed	
when	BC	cells	expressing	negligible	levels	of	HER2	(MCF7)	were	
treated	 with	 2shHG-AHNP-FAM,	 as	 indicated	 by	 lower	
fluorescent	intensities	(Fig.	S9E)	than	it	did	in	SK-BR-3	cells	(Fig.	
S9C).	 Finally,	 treatment	 of	 SK-BR-3	 cells	 with	 2shHG-AHNP-
FAM-Cy	(100	nM)	further	confirmed	the	efficient	entry	and	the	
robustness	 of	 our	 Tat-AHNP-bearing	 constructs,	 as	 both	 Cy5	
and	FAM	dyes	are	detected	in	all	the	target	cells	(Fig.	4I-L).	
				Western	 blot	 analysis	 of	 SK-BR-3	 cells	 treated	with	2shHG-
AHNP	 (100	 nM)	 in	 the	 absence	 of	 transfecting	 agent	
demonstrated	the	ability	of	the	construct	to	impart	the	desired	
RNAi	effect	after	cell	entry	(65%	and	59%	of	GRB7	and	Hsp27	
knockdown;	 Fig.	 4M),	which	 also	 induced	 significant	 levels	 of	
cancer	 cell	 death	 in	 the	 absence	 of	 transfecting	 agent	 [(43	 ±	
2)%	 decrease	 in	 cell	 proliferation;	 Fig.	 4N].	 In	 contrast,	 cells	
remained	unaffected	when	treated	with	a	mixture	of	siRNAs	II	
and	 IV	 and	 with	 nacked	 branched	 2shHG	 (Fig.	 4N).	 Taken	
together,	 these	 results	 demonstrate	 the	 ability	 of	 AHNP-
bearing	2shRNA	conjugates	to	enter	HER2+	cells	in	the	absence	
of	 transfecting	agent,	which	 is	 translated	 in	a	 significant	anti-
proliferative	activity,	due	to	specific	GRB7/Hsp27	silencing.	The	
specificity	 of	 this	 approach	 offers	 clear	 advantages	 over	
cationic-liposome	 based	 drug	 delivery,	 due	 to	 its	 ability	 to	
selectively	deliver	the	two	RNA	drugs	to	the	target	tumor	cell.	
				In	 summary,	 we	 have	 created	 a	 new	 RNA	 nanobinder	 of	
great	potential	 in	the	treatment	of	complex	diseases	that	rely	
on	the	use	of	multiple	drugs.	This	bifunctional	RNA	design	acts	
as	 a	 co-delivery	 system	 able	 to	 administer	 two	 different	
shRNAs	 simultaneously,	 improving	 therapeutic	 efficacy.	 The	
functionalization	 of	 the	 construct	 with	 potentially	 reactive	
groups	 (alkynyl)	 opens	 the	 door	 to	 the	 attachment	 of	
accessory	molecules	which	can,	for	example,	induce	delivery	to	
desired	cells.	As	a	proof	of	concept,	we	have	created	2shRNA	
derivatives	 designed	 to	 target	 wild	 type	 and	 Lap-resistant	
HER2+	 BC	 cells	 and	 functionalized	 with	 a	 peptide	 carrier	
targeting	 the	 HER2	 receptor	 and	 two	 differently	 colored	









Fig.	 4	 (A-L)	 Confocal	 microscopy	 images	 of	 SK-BR-3	 cells	 treated	
with	2shHG-FAM-Cy	(A-D),	siRNA	II-FAM	+	siRNA	 IV-Cy	(E-H)	in	the		
presence	 of	 Lipofectamine,	 and	 with	 2shHG-AHNP-FAM-Cy	 in	 the	
absence	of	Lipofectamine	(I-L).		(A,E,I)	Green	channel	(FAM),	(B,F,J)	
red	 channel	 (Cy5),	 (C,G,K)	 blue	 channel	 (Hoechst	 (nuclei)),	 (D,H,L)	
merged	 views.	 (M,N)	 Western	 blot	 analysis	 and	 anti-proliferative	
studies	 of	 SK-BR-3	 cells	 treated	 with	 2shRNAs	 in	 the	 absence	 of	
Lipofectamine.	
	
				agent.	 As	 the	 BC6	modification	 is	 located	 at	 the	 ends	 and	
central	part	of	the	branched	structure,	it	could	be	compatible	
with	 conventional	 biostable	 chemistries	 at	 internal	 positions	 (like	
phosphorothioate	 chemistries)	 to	 give	 rise	 to	 extremely	 robust	
constructs,	 thus	 further	 improving	 the	 properties	 of	 our	 2shRNA	
technology.	
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